Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Arthur Bregman

Psychiatry Coral Gables, FL Medical Doctor

NPI 1538102397 CMS profile 115128

1550 Madruga Ave Ste 406, Coral Gables, FL 33146

Open in the dashboard

General payments

$4,485

272 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Arthur Bregman of Coral Gables, FL is reported in the CMS Open Payments database as having received $4,485 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $28 2
2023 General $28 1
2022 General $178 12
2021 General $1,104 68
2020 General $758 39
2019 General $2,388 150

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arthur Bregman
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Arthur Bregman were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Arthur Bregman Psychiatry median Middle half National median
2019 $2,388 $184 $59–$605 $163
2020 $758 $119 $36–$372 $114
2021 $1,104 $143 $43–$576 $132
2022 $178 $153 $50–$590 $149
2023 $28 $170 $56–$651 $160
2024 $28 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,300 70 payments
  2. Sunovion Pharmaceuticals Inc. $706 35 payments
  3. AbbVie, Inc. $445 30 payments
  4. Shire North American Group Inc $330 23 payments
  5. Otsuka America Pharmaceutical, Inc. $325 17 payments
  6. Lundbeck LLC $301 19 payments
  7. Allergan Inc. $299 32 payments
  8. Neos Therapeutics, LP $203 12 payments
  9. Ironshore Pharmaceuticals Inc. $171 14 payments
  10. Vanda Pharmaceuticals Inc. $98 4 payments
  11. Other $308 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,485 272 payments
Products named General payments · program years 2019–2024
  1. TRINTELLIX Neuroscience $866 49 payments
  2. LATUDA $706 35 payments
  3. VRAYLAR Neuroscience $445 30 payments
  4. VYVANSE $391 26 payments
  5. Trintellix Central Nervous System (CNS) $372 18 payments
  6. VRAYLAR Neuroscience $299 32 payments
  7. REXULTI Psychiatry $263 16 payments
  8. Adzenys XR-ODT $203 12 payments
  9. COTEMPLA XR-ODT $203 12 payments
  10. REXULTI Psychiatry $199 10 payments
  11. Other $839 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,048

Median for Psychiatry: 574

Drug cost

$25,767

Median for Psychiatry: $27,624

Branded share of claims

22.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aripiprazole Generic 57 $4,187
Bupropion Xl Bupropion Hcl Brand 74 $2,950
Haloperidol Generic 32 $2,773
Fluvoxamine Maleate Generic 30 $2,689
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 70 $1,931
Trazodone Hcl Generic 73 $1,547
Quetiapine Fumarate Generic 71 $1,524
Risperidone Generic 69 $1,486
Divalproex Sodium Generic 26 $1,208
Guanfacine Hcl Er Guanfacine Hcl Brand 20 $1,015

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$11,233

Medicare's payments for the services billed

Medicare patients

48

Average age 55

Services billed

240

28 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 52%
High blood pressure 50%
Arthritis 35%
Ischemic heart disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
  • Corium, Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record